A Prospective, Multicenter, Randomized Controlled Trial of Fastigial Nucleus Stimulation in Patients With Coronary Heart Disease
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Observe the changes of serum SOD（Superoxide dismutase） after treatment.
Study Overview
Brief Summary
To observe the effects of fastigial nucleus stimulation on serum inflammation, oxidative stress related factors, cardiac autonomic function and prognosis in patients with coronary heart disease
Detailed Description
In recent years, with the improvement of the material living standards of the investigators residents and the change of working lifestyle, the prevalence and mortality of coronary heart disease (CHD) in urban and rural residents in China have increased year by year. According to statistics, the number of patients with coronary heart disease in China is currently 11 million. Coronary heart disease has become a major health problem in China. At present, it is found that inflammatory reaction and oxidative stress factors are involved in the occurrence and development of coronary heart disease, and their indicators such as heart rate variability are related to the prognosis of coronary heart disease. Fastigial nucleus stimulation (FNS) has been widely used in the treatment of various diseases such as cerebrovascular disease, migraine, and eye diseases. The study found that FNS can reduce inflammatory cytokines and oxidative stress factors in ischemic myocardium and improve heart rate variability in rats with myocardial infarction. The aim of this study was to investigate whether FNS can improve the aforementioned indicators and clinical outcomes in patients with coronary heart disease.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Coronary angiography was performed after admission, and coronary heart disease was diagnosed (coronary angiography showed at least one coronary artery with a diameter reduction of ≥50% from more than two different angles)
- •Patients and their families agreed and signed informed consent
Exclusion Criteria
- •Severe chronic heart failure, and LVEF <30%
- •Body temperature > 38 ° C and / or combined with severe infection in any system
- •Severe liver and kidney dysfunction
- •Malignant tumor
- •Autoimmune diseases
- •High blood pressure and diabetes with severe comorbidities
- •Use of implantable electronic devices
- •Intracranial implanted vascular stents
- •Surface treatment electrode conductive materials Allergic or mastoid skin lesions
Arms & Interventions
standard medication+fastigial nucleus stimulation
- fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days.
- standard medication:Refer to the "Guidelines for Rational Use of Coronary Heart Diseases"
Intervention: Standard treatment (Drug)
standard medication
standard medication:Refer to the "Guidelines for Rational Use of Coronary Heart Diseases"
Intervention: Standard treatment (Drug)
standard medication+fastigial nucleus stimulation
- fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days.
- standard medication:Refer to the "Guidelines for Rational Use of Coronary Heart Diseases"
Intervention: Fastigial Nucleus Stimulation (Device)
Outcomes
Primary Outcomes
Observe the changes of serum SOD（Superoxide dismutase） after treatment.
Time Frame: baseline,1month
Observe the changes of serum SOD levels（ng/ml）after treatment in the two groups of patients.
Observe the changes of serum GPX（Glutathione peroxidase） after treatment.
Time Frame: baseline,1month
Observe the changes of serum GPX levels（ng/ml）after treatment in the two groups of patients.
Observe the changes of serum AOPP（Advanced oxidation protein product） after treatment.
Time Frame: baseline,1month
Observe the changes of serum AOPP levels（umol/l）after treatment in the two groups of patients.
Observe the changes of SDANN（Standard Deviation of mean NN intervals in 5-minute recordings） after treatment.
Time Frame: baseline,1month
Observe the changes of SDANN（ms）after treatment in the two groups of patients.
Observe the changes of serum TNF-α after treatment.
Time Frame: baseline,1month
Observe the changes of serum TNF-α levels（pg/ml）after treatment in the two groups of patients.
Observe the changes of serum Lp-PLA2 after treatment.
Time Frame: baseline,1month
Observe the changes of serum Lp-PLA2 levels（ng/ml）after treatment in the two groups of patients.
Observe the changes of serum hs-CRP after treatment.
Time Frame: baseline,1month
Observe the changes of serum hs-CRP levels（mg/l）after treatment in the two groups of patients.
Observe the changes of SDNN（Standard Deviation of the NN intervals） after treatment.
Time Frame: baseline,1month
Observe the changes of SDNN（ms）after treatment in the two groups of patients.
Observe the changes of rMSSD（square root of the mean squared differences of successive NN intervals） after treatment.
Time Frame: baseline,1month
Observe the changes of rMSSD（ms）after treatment in the two groups of patients.
Observe the changes of serum IL-6 after treatment.
Time Frame: baseline,1month
Observe the changes of serum IL-6 levels（pg/ml）after treatment in the two groups of patients.
Observe the changes of serum MDA（Malondialdehyde） after treatment.
Time Frame: baseline,1month
Observe the changes of serum MDA levels（nmol/ml）after treatment in the two groups of patients.
Observe the changes of SDNN In（Average of the standard deviation of the NN interval every 5 minutes） after treatment.
Time Frame: baseline,1month
Observe the changes of SDNN In（ms）after treatment in the two groups of patients.
Observe the changes of pNN50（Percentage of the difference between adjacent RR intervals >50ms ） after treatment.
Time Frame: baseline,1month
Observe the changes of pNN50（%）after treatment in the two groups of patients.
Secondary Outcomes
- Follow-up rate of major cardiovascular events(12months)